We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

EUROSPITAL SPA

Eurospital Spa manufactures and commercializes pharmaceutical products, medical-surgical and diagnostic devices and a... read more Featured Products: More products

Download Mobile App




Diagnostic Accuracy of Immunochromatographic Fecal Calprotectin Assay Evaluated

By LabMedica International staff writers
Posted on 20 Mar 2016
Fecal calprotectin is a noninvasive marker for bowel diseases and it is of high value for following disease activity in Crohn's disease (CD) and ulcerative colitis (UC).

The diagnostic performance of the recently introduced immunochromatographic assay has been evaluated in comparison to the well-known enzyme-linked immunosorbent assay (ELISA) tests for calprotectin assay to obtain a rapid diagnosis of bowel inflammation in pediatric patients.

Scientists at the Burlo Garofolo Pediatric Institute (Trieste, Italy) obtained fecal samples from 148 pediatric subjects ranging in ages from 2 to 18 years, 70 were males and 78 were females, 44 of which were affected by intestinal diseases. More...
The pediatric subjects included 104 healthy subjects, 29 with and Crohn’s disease (CD), and 15 with Ulcerative colitis (UC). All patients were diagnosed in acute phase. All stool samples were collected in plastic containers and frozen at -20 °C without urine contamination.

The commercial kits used were the PhiCal Calprotectin ELISA based on two-site sandwich technique with two selected monoclonal antibodies, cutoff of 50 mg/kg (Pantec Immunodiagnostic; Milan, Italy); Calprest ELISA based on polyclonal antibodies against fecal calprotectin, cutoff of 100 mg/kg (Eurospital; Trieste, Italy); and Eurospital’s CalFast Immunochromatographic assay with a cutoff of 100 mg/kg combined with a mixture of anti-calprotectin polyclonal and monoclonal antibodies. Once extracted, the sample is diluted and transferred into the diagnostic device. A dedicated reader provides the concentration of calprotectin in the sample in just 15 minutes.

The scientists found that the sensitivity and specificity of CalFast, CalPrest, and PhiCal were 86.4%, 88.6%, and 93.2% and 86.6%, 74%, and 64.4%, respectively. The area under the curve, obtained from receiver operating characteristic analysis, indicated the lack of significant difference among all the kits used. The authors concluded that the immunochromatographic assay demonstrated good diagnostic predictive values, comparable to those of the ELISA methods, and may represent a valid alternative in order to save operators' time. The test, in fact, has a short turnaround time and does not need a specific ELISA instrumentation. The study was published on February 15, 2016, in the Journal of Clinical Laboratory Analysis.

Related Links:

Burlo Garofolo Pediatric Institute
Pantec Immunodiagnostic 
Eurospital 



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.